Hiroyuki Tanaka

Two girls with a neonatal screening-negative 21-hydroxylase deficiency requiring treatment with hydrocortisone for virilization in late childhood

K. Ozono, T. Hasegawa, Shinsuke Onuma, 2021, Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology.

Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study

R. Eastell, S. Ralston, M. Brandi, 2022, Calcified Tissue International.

Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial

F. Glorieux, H. Cheong, E. Sochett, 2019, The Lancet.

Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial

F. Glorieux, H. Cheong, E. Sochett, 2019, The Lancet.

Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial

K. Ozono, T. Kubota, Y. Seino, 2022, Journal of the Endocrine Society.

Fetal ultrasonographic findings including cerebral hyperechogenicity in a patient with non‐lethal form of Raine syndrome

N. Okamoto, F. Miya, Akihito Takeuchi, 2018, American journal of medical genetics. Part A.

Rapid Progression of Heterotopic Ossification in Severe Variant of Fibrodysplasia Ossificans Progressiva with p.Arg258Gly in ACVR1: A Case Report and Review of Clinical Phenotypes

Kosei Hasegawa, Hiroyuki Tanaka, Hirokazu Tsukahara, 2022, Case reports in genetics.

Achondroplasia: Recent advances in diagnosis and treatment

Hiroyuki Tanaka, 1997, Acta paediatrica Japonica : Overseas edition.

A novel pathogenic variant p.Asp797Val in IFIH1 in a Japanese boy with overlapping Singleton‐Merten syndrome and Aicardi‐Goutières syndrome

H. Tsukahara, Kosei Hasegawa, Hiroyuki Tanaka, 2021, American journal of medical genetics. Part A.

Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies

K. Ozono, Y. Takeuchi, Y. Imanishi, 2023, Advances in Therapy.

Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia

F. Glorieux, H. Cheong, Hiroyuki Tanaka, 2021, Calcified Tissue International.